Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 65.00 65.20 65.60 65.60 64.00 64.00 5,992,801 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 26.5 296

Ekf Diagnostics Share Discussion Threads

Showing 3176 to 3200 of 3475 messages
Chat Pages: 139  138  137  136  135  134  133  132  131  130  129  128  Older
DateSubjectAuthorDiscuss
10/3/2021
15:38
Worthy of note - Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in... 10/03/2021 3:31pm PR Newswire (US) NEW YORK, March 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today it has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021 and ranked first in the Joint Ventures category. Kantaro launched in May 2020 in response to the COVID-19 pandemic to make a high-performing SARS-CoV-2 IgG antibody test created at Mount Sinai broadly accessible worldwide. "We are honored to be named one of the World's Most Innovative Companies by Fast Company and recognized for our work to ensure Kantaro antibody test kits are widely available to aid in the global battle against COVID-19," said Sara Barrington, chief commercial officer at Kantaro. Marketed as COVID-SeroKlir, the Kantaro test measures the presence and precise level of IgG antibodies — the same type of antibodies produced as part of the immune response to COVID-19. Unlike most other antibody tests, COVID-SeroKlir reports a numerical answer, not just a yes/no qualitative result. It can be used in any authorized clinical testing laboratory without the need for proprietary equipment. Kantaro also launched COVID-SeroIndex for research use only. Kantaro achieved a variety of milestones this year, including a commercial partnership with Bio-Techne Corporation (NASDAQ: TECH) to manufacture, sell and distribute the Kantaro tests at scale; receiving CE marking for COVID-SeroKlir and COVID-SeroIndex; and securing Emergency Use Authorization by the FDA for COVID-SeroKlir. Kantaro also established a global presence in the UK, Europe and South America through strategic partnerships with EKF Diagnostics, a global leader in diagnostic testing, and Atrys Health, a biomedical company dedicated to providing diagnostic services and medical treatments of excellence. The World's Most Innovative Companies is Fast Company's signature franchise and one of its most highly anticipated editorial efforts of the year. This year's Most Innovative Companies list honors 463 businesses from 29 countries that have found a way to be resilient in the past year and impact their industries and culture as a whole. It provides both a snapshot and a road map for the future of innovation across the most dynamic sectors of the economy. Full release - http://uk.advfn.com/stock-market/london/RENX/share-news/Kantaro-Biosciences-Named-to-Fast-Companys-Annual/84544929?xref=newsalert EKF is a distributor for the Kantaro antibody test kits
wan
10/3/2021
14:50
Just as a reminder (and partly in reference to my earlier post 1586), we have yet to see the financial effects from the following - New contract manufacturing opportunities at Boerne, Texas site for delivery in 2021 for five new customers: • Customer 1: RNA detection kits • Customer 2: CRISPR Human RNA depletion kit • Customer 3: Forensic kits • Customer 4: Next generation sequencing pathogen detection kits • Customer 5: Genome assembly and genetic variant detection kits Strong pipeline of opportunities to leverage capacity at Elkhart and South Bend, Indiana, facilities: • Oragenics: Enzymes for use in research • Ixcela: Food grade fermentation digestive protein • iGenomX: Molecular KOD enzyme (used in PCR) Not to mention the completion of Quo-Test cartridge registration in China expected by December 2020 or early 2021, with negotiations apparently already underway with potential distributors to sell analysers and tests in 2021.
wan
10/3/2021
13:29
You have to love the plc world. One can bet their last pennies that senior managers will always be very able to look after themselves.
tongosti
10/3/2021
10:20
Cheers wan, an impressive product for a globally prevalent need.
rivaldo
10/3/2021
07:17
9th March 2021 EKF globally launches STAT-Site® WB β-ketone and glucose handheld analyzer EKF Diagnostics, the global in vitro diagnostics company, announces the global launch of its STAT-Site® WB handheld analyzer which delivers β-ketone and glucose measurements from whole blood in seconds. This follows the securing of its CE mark certification alongside its FDA CLIA-waiver, meaning that the portable, dual-purpose analyzer is ideal for professional use in the management of diabetes patients. The STAT-Site® WB is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or BHB) and glucose in whole blood taken from capillary or venous samples. The easy-to-use analyzer is reagent free, utilizing two different test strips to deliver results in just 10 seconds for β-ketones and 5 seconds for glucose. This enables clear and comprehensive management of diabetes patients displaying early symptoms of ketosis, ensuring their rapid treatment and subsequent regular monitoring. βHB is used to aid the diagnosis and monitoring of patients with ketosis (diabetic ketoacidosis or DKA). As β-HB accounts for 78% of all ketones present in the body, and is the first to appear during ketosis, it provides the clearest indication of a patient’s condition before and after treatment. The STAT-Site WB is calibrated to the gold standard Liquicolor Beta-Hydroxybutyrate method, meaning that it delivers laboratory accurate results within seconds near to the patient. Further ensuring results accuracy, the handheld analyzer is simple and intuitive to use, even for inexperienced users. The STAT-Site WB auto-starts when a test strip is inserted and will also automatically detect if it is a BHB or glucose test to be undertaken. Just 1 µL of whole blood is required for direct analysis and the system will also detect and alert if insufficient blood is available. An automatic strip ejection function ensures that cross contamination is avoided. Also making it ideal for remote testing, the analyzer uses two 1.5V AAA alkaline batteries which are easy to obtain and replace, whilst test strips are available individually foil wrapped or in a vial with a shelf life of six months once opened. Results are clearly displayed on a large LCD screen interface with capacity for up to 400 measurements to be stored on the system – these can be downloaded via a mini USB lead. “STAT-Site WB provides an affordable, easy-to-use technology that can help to reduce the cost of long-term healthcare of the growing diabetic and pre-diabetic population globally,” said Gavin Jones, Head of Product Management, EKF Diagnostics. “Having direct access to lab quality β-ketone and glucose near patient results ensures the practitioner has the essential data needed to make informed clinical or lifestyle decisions in seconds.” Full release - hTTps://www.ekfdiagnostics.com/ekf-globally-launches-stat-site-wb-ketone-and-glucose-handheld-analyzer.html To put this global launch into some context in terms of importance and need - Increasing Hospitalizations for DKA: A Need for Prevention Programs Priyathama Vellanki and Guillermo E. Umpierrez Diabetes Care 2018 Sep Diabetic ketoacidosis (DKA) is a diabetes emergency associated with high morbidity in patients with diabetes (1). In patients with type 1 diabetes, DKA can occur at new onset of diabetes but can also recur due to lack of insulin use and precipitating causes such as infection. DKA is a hallmark of type 1 diabetes; however, DKA is increasingly recognized in patients with type 2 diabetes (2). In contrast to patients with type 1 diabetes who require life-long insulin therapy, most patients with type 2 diabetes who present with DKA can recover insulin secretion and maintain glycemic control with oral antidiabetes medications (3). While inpatient mortality rates for DKA are generally very low, <1% in the U.K. (4) and in the U.S. (5), DKA is the leading cause of mortality among children and young adults with type 1 diabetes, accounting for ∼50% of all deaths in this population (1). In addition, rates vary substantially based on health care setting; a recent analysis conducted in India reported that up to 30% of hospitalized DKA cases result in inpatient death (6). hTTps://care.diabetesjournals.org/content/41/9/1839
wan
09/3/2021
13:54
I think ppl are right. I should filter you. I appreciate bear cases I don't appreciate trolls that can't get their message across in simple language. Tong is now filtered
mg1982
09/3/2021
13:52
Ignorance is bliss. Long this may continue - unless market boats get heavily tipped on one side here and there, how can one make money?Love these boards.
tongosti
09/3/2021
13:50
MG1982 - suggest you just filter her/him like most of us do then you will not provoke yet more replies tongosti 9 Mar '21 - 10:34 - 1593 of 1595 (Filtered) MG1982 9 Mar '21 - 13:12 - 1594 of 1595 In English pls Tong? Thanks tongosti 9 Mar '21 - 13:47 - 1595 of 1595 (Filtered)
sharw
09/3/2021
13:47
It's not one's fault that he/she may have never worked in the industry. What is a problem (for that particular individual of course - whether they know it or not) is that if he/she does not understand a very basic comment (incidentally with this being number 1 question a smart portfolio manager asks before initiating a position, ANY position) - then one shouldn't gamble their savings in the market before they go back to the drawing board.
tongosti
09/3/2021
13:12
In English pls Tong? Thanks
mg1982
09/3/2021
10:34
et action 101Over the longer term, it's fundamentals that drive prices. However they have a habit of showing in the price way before they show in fundamentals. This is precisely where most fundamentally driven players get lost - as understanding such a key property of markets inevitably means that one needs to go way beyond fundamentals (and shorten their time horizons to accommodate risk management) to make (and protect their) money. Any wonder the very top - folks were laughing at doctors orders then - took place the day the Pfizer vaccine was announced? Going forward (not that many on here can or are willing to think about it, unfortunately) the most relevant question is: what exactly is Mr Market currently discounting?
tongosti
09/3/2021
10:18
This one? https://www.proactiveinvestors.co.uk/companies/news/943260/sourcebio-international-score-high-with-fixture-for-england-rugby-coronavirus-testing-contract-943260.html
jacks13
09/3/2021
10:06
This interview with #SBI's CEO is also very relevant to #EKF. Testing is here to stay at least for calendar year 2021.
mg1982
09/3/2021
07:24
Could be any minute now... Bear with him chaps.
tongosti
08/3/2021
15:52
GG I thought you had quit smoking (in the sequel). Went back to it again?
tongosti
08/3/2021
13:02
ANA is the best UK cannabis stock Share price 1.1p Only £6.4m mkt cap Fastest growing sector worldwide Will have first mover advantage in UK Same growers as GW Pharma 4 biggest shareholders hold over 50% BOD own 30% Massively undervalued (£6.4m mkt cap) Near term multi bagger on license approval Partners with leading prof , scientists etc Primed for a RTO/ main listing (price driver) Under the radar (most chased MXC,CBX) Looking to bring a product to market Off take agreement in place already Will be producing 200 TONS per year (200,000 kilos) Has the most land out of every cannabis co Fully funded for phase 1 UK medical cannabis growing 20% month Only 584m shares in issue Hardly any available in open market Will apply for a commercial license too Worth getting in on the ground floor imho. hTTps://businesscann.com/work-on-12m-medicinal-cannabis-cultivation-facility-held-up-by-covid-19-uk-travel-ban/ hTTps://anandadevelopments.com/tiamat-agriculture-ltd/
gordan ghetto
07/3/2021
22:09
Brilliant. Am sure every one on this board is well versed into the technicalities of the article you have copied and pasted.
tongosti
07/3/2021
17:29
I have been catching up in a few areas that I have neglected. In 2018 EKF Diagnostics signed an exclusive agreement with Oragenics, Inc. (NYSE American: OGEN), a Florida-based biopharmaceutical company, for the manufacturing of Oragenics’ lantibiotic bulk drug substances in the United States. I note the following Presentation and recent news flow - • Lantibiotics are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacterial strains to attack competing bacterial strains • Platform: >700 lantibiotic structures created, potentially generating a pipeline of new compounds • Platform provides potential for development in multidrug resistant infections: − Methicillin Resistant Staphlococcus aureus (MRSA) − Vancomycin Resistant Enterococci (VRE) − Virulent Clostridium difficile − Gram(-) infections Novel class of peptide antibacterial compounds called Lantibiotics • Activity against a variety of MDR infections, believed to be the next human health crisis • Lead lantibiotic OG716 addresses C. difficile – a significant infection identified by the CDC. They estimate filing for FDA IND (Investigational New Drug (IND) Application) in Q2 2021, but this was subject to having adequate available capital to complete requisite studies. Presentation November 2020, Lantibiotics page 18 onwards - hTTps://d1io3yog0oux5.cloudfront.net/_3163672321476757073a795d523eea69/oragenics/db/224/647/pdf/14558382v1+-+Oragenics+Investor+Deck+11+14+20+AGP+FINAL.pdf February 12, 2021 TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics&rdquo; or the “Company&rdquo;) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Officer of Oragenics, said, “We are delighted that we were able to raise capital to fund our operations through a number of anticipated key value-creating milestones towards the initiation of the Phase 2 clinical trial of our SARS CoV-2 vaccine, Terra CoV-2. In addition, we will be able to advance our lantibiotics program, which is directed at solving the problem of multidrug-resistant organisms. hTTps://www.oragenics.com/news-media/press-releases/detail/123/oragenics-announces-recent-capital-raise-and-warrant Oragenics are thus funded to advance and file for FDA IND, and I assume they will require further product to support that. And if that filing is ultimately successful, one can imagine that very large bulk volumes will be required to address such an important issue as antibiotic-resistant infections (this might also be of particular interest to ESG Investment Funds?)
wan
07/3/2021
16:55
Mirandaj....You may be interested in the interview earlier today with Susan Hopkins from Public Health England on the Andrew Marr show (if you had not seen it), regarding lateral flow tests, confirmatory pcr tests, sequencing/variants and being very prepared for a difficult autumn/winter (Covid and Flu, even if it does not arrive) - For the Susan Hopkins interview scroll to just over 30 mins in - hTTps://www.bbc.co.uk/iplayer/episode/m000t17r/the-andrew-marr-show-07032021
wan
07/3/2021
09:12
Lateral Flow tests do tend to have a reputation as giving too many false positives and negatives and this may well increase with the children self testing... https://bidstats.uk/tenders/2021/W09/746193438 Tenders for £8 billion Lateral Flow.
mirandaj
07/3/2021
09:07
Schools are back tomorrow so perhaps he will be too busy taunting others in the playground during the day instead.
darryn1
06/3/2021
15:59
Sometime ago after the Tongue tried to directly message me decided to firstly not read it and secondly to block his/her messages in the forum. The result has been a tidier screen populated with comments and observations from people with some insight into what is happening to the company and its environment rather than peddling idle comments from the sidelines based on hunches a few shareholders may be selling or buying, and trying to look for something more sinister than they are are buying something else whether shares or completely different and not playing hers/his hunches about market directions.
welshborderer
05/3/2021
22:17
Whatever you say Carlo.
tongosti
05/3/2021
15:19
Sense of humour very intact. Loving life. And it gives me a glow to know I have had nothing to do with siring the likes of you.....
charliec51
05/3/2021
15:19
Sense of humour very intact. Loving life. And it gives me a glow to know I have had nothing to do with siring the likes of you.....
charliec51
Chat Pages: 139  138  137  136  135  134  133  132  131  130  129  128  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210516 13:21:05